MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
He H, Yao M, Zhang W, Tao B, Liu F, Li S, Dong Y, Zhang C, Meng Y, Li Y, et al. Cell Mol Immunol. 2016 Sep; 13(5):658-68. Epub 2015 Jul 20.